

REMARKS

Applicant elects Group I, claims 54-64, for prosecution on the merits. Further, applicant selects salbutamol as the species of beta 2 agonist.

The non-elected claims have been canceled, without prejudice or disclaimer. A detailed listing is presented, with appropriately defined status identifiers, for all claims that are or were in the application, irrespective of whether the claim(s) remain under examination. Upon entry of the present amendment, claims 58-61 and 64 will be pending.

Applicant believes that the present application is in condition for allowance. An early indication to this effect is requested. Examiner Bland is invited to contact the undersigned directly, should she feel that any issue warrants particular consideration.

In addition, the Commissioner is hereby authorized to charge any additional fees, which may be required under 37 CFR §§ 1.16-1.17, and to credit any overpayment to Deposit Account No. 19-0741. Should no proper payment accompany this response, then the Commissioner is authorized to charge the unpaid amount to the same deposit account. If any extension is needed for timely acceptance of submitted papers, then Applicant petitions for such extension under 37 CFR §1.136 and authorizes payment of related extension fees from the deposit account.

Respectfully submitted,

Date 23 July 2007

By S. A. Bent

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768